摘要
奥克纤溶酶（Ocriplasmin）作为只保留酶活性片段的重组丝氨酸蛋白酶类的纤溶酶,通过诱导玻璃体液化及减弱玻璃体黄斑粘连,起到药物性玻璃体后脱离的作用,避免了手术完成玻璃体后脱离创伤大、脱离不彻底等缺陷.系统性临床试验已表明奥克纤溶酶缓解症状性玻璃体黄斑粘连的作用.美国及欧盟已批准奥克纤溶酶治疗症状性玻璃体黄斑粘连,推荐治疗剂量为125 μg.本文将就奥克纤溶酶治疗症状性玻璃体黄斑粘连的研究进展做一综述.
Ocriplasmin is a recombinant truncated form of human serine protease plasmin with proteolytic activity to induce vitreous liquefaction and weaken vitreomacular adhesion,thereby facilitating posterior vitreous detachment and acting as a potential alternative to replace the more traumatic vitrectomy which can result in incomplete vitreoretinal separation.Intravitreal ocriplasmin for symptomatic vitreomacular adhesion has been systematically evaluated in clinical trials.Ocriplasmin at the recommended dose of a single 125 μg intravitreal injection has recently been approved for the treatment of symptomatic VMA in the USA and EU.This review is aiming to highlight the research update of ocriplasmin.
出处
《中华眼科杂志》
CAS
CSCD
北大核心
2014年第11期866-870,共5页
Chinese Journal of Ophthalmology
关键词
纤维蛋白溶酶
肽碎片
玻璃体
组织黏连
玻璃体脱离
Fibrinolysin
Peptide fragments
Vitreous body
Tissue adhesions
Vitreous detachment
